At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...